Nivalis Therapeutics nivalis.com

Nivalis Therapeutics, formerly N30Pharma, is developing a novel class of disease modifying therapies that are designed to preserve intracellular GSNO (S-nitrosoglutathione), an endogenous molecule with cell signaling effects that are implicated in the pathophysiology of cystic fibrosis (CF).The Company's lead candidate, N91115 initially targets patients with the F508del mutation, the most common disease causing mutation in CF.

Nivalis Therapeutics, formerly N30Pharma, is developing a novel class of disease modifying therapies that are designed to preserve intracellular GSNO (S-nitrosoglutathione), an endogenous molecule with cell signaling effects that are implicated in th...Show all

See All Exits Recent Exits

Phone: 720-945-7700

Fax:

3122 Sterling Circle
Suite 200
Boulder, 80301
Colorado, United States

Nivalis Therapeutics - Investments & Acquisitions

Show Real Data Nivalis Therapeutics Investments
See all Recent Investments
Date Company Round Amount Co-investors
2017-07-24Alpine Immune SciencesReverse Merger
See all 1 investments